TEICHOS LABORATORIES, LLC — Department of Health and Human Services SBIR Phase I: NCIRD

TEICHOS LABORATORIES, LLC — SBIR Phase I award from Department of Health and Human Services.

Amount
$243,000
Agency
Department of Health and Human Services · Centers for Disease Control and Prevention
Program / Phase
SBIR · Phase I
Topic
NCIRD
Solicitation
PA20-260
NAICS
Place of performance
IN
Period
2021-09-30 → 2022-09-29

Description

ABSTRACT: Teichos technology, amacromolecularplatformofpeptidoglycanbiologics(sPGN)producedbyproprietary chemoenzymatictotalsynthesis,offersimprovedinfluenzavaccinesthroughsignificantlyimprovedadjuvant performance. TL-001, a stimulatory sPGN, demonstrated adjuvant activity at low doses in standard laboratory vaccination model. We propose to evaluate TL-001 for its potential utility as an influenza vaccine adjuvant by confirming its mechanism of action in monocyte and macrophage cultures and its ability to enhance antibody and T cell responses using an influenza H1 subunit vaccination model in mice.